Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Pharmacol
Egile Nagusiak: Wade, Janet R., Parker, Gerry, Kosutic, Gordana, Feagen, Brian G., Sandborn, William J., Laveille, Christian, Oliver, Ruth
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2015
Gaiak:
Pharmacometrics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6680228/
https://ncbi.nlm.nih.gov/pubmed/25735646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.491
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak